NHS saves more than £700m on medicines costs
A huge part of the saving was made up by AbbVie’s Humira losing its patent.
Read More
Author: Anna Smith
AbbVie discontinues Rova-T programme
An Independent Data Monitoring Committee recommended terminating the trial, following a failure to demonstrate survival benefit.
Read More
EU nod for Giapreza
In July the EMA’s CHMP supported granting a marketing authorisation for the drug.
Read More
Immunicum’s ilixadencel successful in kidney cancer
The drug achieved complete tumour responses in five out of 45 metastatic kidney cancer patients, compared to one in 25.
Read More
White matter affects response to brain stimulation therapy
The team ultimately found that “people with stronger white matter connections in their brain had better improvement with stimulation.”
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
